Kohjiro Ueki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7910460/publications.pdf

Version: 2024-02-01

76326 60623 10,891 86 40 81 citations h-index g-index papers 93 93 93 13654 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	An antisense transcript transcribed from Irs2 locus contributes to the pathogenesis of hepatic steatosis in insulin resistance. Cell Chemical Biology, 2022, , .	5.2	2
2	Metagenomic Identification of Microbial Signatures Predicting Pancreatic Cancer From a Multinational Study. Gastroenterology, 2022, 163, 222-238.	1.3	61
3	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	1.4	6
4	Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. Journal of Gastroenterology, 2021, 56, 261-273.	5.1	28
5	Preparation and culture of bone marrow-derived macrophages from mice for functional analysis. STAR Protocols, 2021, 2, 100246.	1.2	94
6	MEK/ERK Signaling in \hat{l}^2 -Cells Bifunctionally Regulates \hat{l}^2 -Cell Mass and Glucose-Stimulated Insulin Secretion Response to Maintain Glucose Homeostasis. Diabetes, 2021, 70, 1519-1535.	0.6	9
7	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial with a focus on Asia. Diabetes, Obesity and Metabolism, 2021, 23, 1886-1891.	4.4	18
8	SLC15A4 mediates M1-prone metabolic shifts in macrophages and guards immune cells from metabolic stress. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
9	Comorbidities and complications in Japanese patients with type 2 diabetes mellitus: Retrospective analyses of J-DREAMS, an advanced electronic medical records database. Diabetes Research and Clinical Practice, 2021, 178, 108845.	2.8	11
10	Prevention of Worsening Diabetes through Behavioral Changes by an IoT-based Self-Monitoring System in Japan (PRISM-J): Study design and rationale for a multicenter, open-label, randomized parallel-group trial. GHM Open, 2021, 1, 3-11.	0.6	0
11	Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care, 2021, 44, 2542-2551.	8.6	42
12	Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). BMJ Open Diabetes Research and Care, 2021, 9, e001787.	2.8	15
13	Factors associated with the degree of glycemic deterioration among patients with type 2 diabetes who dropped out of diabetes care: A longitudinal analysis using medical claims and health checkup data in Japan. Journal of Diabetes Investigation, 2021, , .	2.4	1
14	Associations between diabetes duration and self-stigma development in Japanese people with type 2 diabetes: a secondary analysis of cross-sectional data. BMJ Open, 2021, 11, e055013.	1.9	8
15	Comparison of effectiveness and drug cost between dipeptidyl peptidaseâ€4 inhibitor and biguanide as the firstâ€line antiâ€hyperglycaemic medication among Japanese working generation with type 2 diabetes. Journal of Evaluation in Clinical Practice, 2020, 26, 299-307.	1.8	9
16	Insulin- and Lipopolysaccharide-Mediated Signaling in Adipose Tissue Macrophages Regulates Postprandial Glycemia through Akt-mTOR Activation. Molecular Cell, 2020, 79, 43-53.e4.	9.7	29
17	How self-stigma affects patient activation in persons with type 2 diabetes: a cross-sectional study. BMJ Open, 2020, 10, e034757.	1.9	27
18	IL-7R–Dependent Phosphatidylinositol 3-Kinase Competes with the STAT5 Signal to Modulate T Cell Development and Homeostasis. Journal of Immunology, 2020, 204, 844-857.	0.8	9

#	Article	IF	Citations
19	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetes ― A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society ―. Circulation Journal, 2020, 85, 82-125.	1.6	16
20	8. Perspective of the Treatment for Diabetes. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1912-1918.	0.0	0
21	Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. Journal of Gastroenterology, 2019, 54, 64-77.	5.1	21
22	Variation in process quality measures of diabetes care by region and institution in Japan during 2015–2016: An observational study of nationwide claims data. Diabetes Research and Clinical Practice, 2019, 155, 107750.	2.8	23
23	Changes in the quality of diabetes care in Japan between 2007 and 2015: A repeated cross-sectional study using claims data. Diabetes Research and Clinical Practice, 2019, 149, 188-199.	2.8	11
24	Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism. Nature Communications, 2019, 10, 947.	12.8	52
25	3. Recent Progress in the Treatment of Type 2 Diabetes. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 460-467.	0.0	0
26	Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL-4-indeuced M2a-subtype macrophage activation in obesity. Nature Communications, 2018, 9, 4863.	12.8	60
27	Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients. Journal of Gastroenterology, 2018, 53, 1261-1275.	5.1	25
28	The RNA Methyltransferase Complex of WTAP, METTL3, and METTL14 Regulates Mitotic Clonal Expansion in Adipogenesis. Molecular and Cellular Biology, 2018, 38, .	2.3	114
29	Activin B: A potential target to cure diabetes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY62-4.	0.0	0
30	Thermographic findings in a case of type 2 diabetes with foot ulcer due to callus deterioration. Diabetology International, 2017, 8, 328-333.	1.4	8
31	Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. Journal of Diabetes Investigation, 2017, 8, 397-410.	2.4	95
32	Dual Regulation of Gluconeogenesis by Insulin and Glucose in the Proximal Tubules of the Kidney. Diabetes, 2017, 66, 2339-2350.	0.6	61
33	Psychological and behavioural patterns of stigma among patients with type 2 diabetes: a cross-sectional study. BMJ Open, 2017, 7, e013425.	1.9	32
34	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Journal of Diabetes Investigation, 2017, 8, 123-125.	2.4	48
35	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 951-964.	11.4	228
36	CD206+ M2-like macrophages regulate systemic glucose metabolism by inhibiting proliferation of adipocyte progenitors. Nature Communications, 2017, 8, 286.	12.8	178

#	Article	IF	Citations
37	Design of and rationale for the Japan Diabetes compREhensive database project based on an Advanced electronic Medical record System (J-DREAMS). Diabetology International, 2017, 8, 375-382.	1.4	28
38	Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: report of Committee on Causes of Death in Diabetes Mellitus. Diabetology International, 2017, 8, 117-136.	1.4	49
39	Factors Associated With Callus in Patients with Diabetes, Focused on Plantar Shear Stress During Gait. Journal of Diabetes Science and Technology, 2016, 10, 1353-1359.	2.2	28
40	Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology, 2016, 157, 1029-1042.	2.8	116
41	Report of the Japan diabetes society/Japanese cancer association joint committee on diabetes and cancer, Second report. Cancer Science, 2016, 107, 369-371.	3.9	10
42	New glycemic targets for patients with diabetes from the Japan Diabetes Society. Diabetology International, 2016, 7, 327-330.	1.4	6
43	Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity. Nature Communications, 2016, 7, 12977.	12.8	77
44	Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways. Scientific Reports, 2016, 6, 34707.	3.3	8
45	Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. BMJ Open Diabetes Research and Care, 2016, 4, e000123.	2.8	26
46	Report of the Japan Diabetes Society (JDS)/Japanese Cancer Association (JCA) Joint Committee on Diabetes and Cancer, Second Report. Diabetology International, 2016, 7, 12-15.	1.4	11
47	A qualitative study on the impact of internalized stigma on type 2 diabetes self-management. Patient Education and Counseling, 2016, 99, 1233-1239.	2.2	52
48	Association between self-stigma and self-care behaviors in patients with type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Research and Care, 2016, 4, e000156.	2.8	47
49	Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity. Diabetes and Metabolism Journal, 2015, 39, 363.	4.7	47
50	Association between Washing Residue on the Feet and Tinea Pedis in Diabetic Patients. Nursing Research and Practice, 2015, 2015, 1-7.	1.0	4
51	A large-scale, observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 2 diabetes—JDCP study 1. Diabetology International, 2015, 6, 243-251.	1.4	14
52	Insulin Receptor Substrate-2 (Irs2) in Endothelial Cells Plays a Crucial Role in Insulin Secretion. Diabetes, 2015, 64, 876-886.	0.6	33
53	Effects of beraprost sodium, an oral prostacyclin analog, on insulin resistance in patients with type 2 diabetes. Diabetology International, 2015, 6, 39-45.	1.4	1
54	Protocol for a large-scale prospective observational study with alogliptin in patients with type 2 diabetes: J-BRAND Registry. BMJ Open, 2014, 4, e004760-e004760.	1.9	4

#	Article	IF	CITATIONS
55	Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, and Safety of Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Japanese Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics, 2014, 36, 1606-1615.	2.5	26
56	Lung abscess without sepsis in a patient with diabetes with refractory episodes of spontaneous hypoglycemia: a case report and review of the literature. Journal of Medical Case Reports, 2014, 8, 51.	0.8	3
57	Report of the JDS/JCA Joint Committee on Diabetes and Cancer. Diabetology International, 2013, 4, 81-96.	1.4	32
58	Loss of Akt1 in Mice Increases Energy Expenditure and Protects against Diet-Induced Obesity. Molecular and Cellular Biology, 2012, 32, 96-106.	2.3	56
59	Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nature Medicine, 2012, 18, 388-395.	30.7	310
60	The PREDICTIVETM Study: a multinational, prospective observational study to evaluate the safety and efficacy of insulin detemir treatment in patients with type 1 and 2 diabetes $\hat{\epsilon}$ data from the Japan cohort. Diabetology International, 2012, 3, 11-20.	1.4	1
61	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetology International, 2012, 3, 8-10.	1.4	202
62	Adiponectin Enhances Insulin Sensitivity by Increasing Hepatic IRS-2 Expression via a Macrophage-Derived IL-6-Dependent Pathway. Cell Metabolism, 2011, 13, 401-412.	16.2	236
63	Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type $\hat{s} \in \mathcal{S}$ diabetes. Journal of Diabetes Investigation, 2011, 2, 448-456.	2.4	12
64	Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 5753-5758.	7.1	44
65	Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetology International, 2010, 1 , 2-20.	1.4	322
66	Class IA Phosphatidylinositol 3-Kinase in Pancreatic \hat{I}^2 Cells Controls Insulin Secretion by Multiple Mechanisms. Cell Metabolism, 2010, 12, 619-632.	16.2	101
67	Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes Investigation, 2010, 1, 212-228.	2.4	1,206
68	Glucose Effects on Beta-Cell Growth and Survival Require Activation of Insulin Receptors and Insulin Receptor Substrate 2. Molecular and Cellular Biology, 2009, 29, 3219-3228.	2.3	138
69	CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine, 2009, 15, 914-920.	30.7	1,887
70	Type 1 Diabetes Mellitus Associated with Vogt-Koyanagi-Harada Syndrome, Palmoplantar Pustulosis, and Hashimoto's Thyroiditis. The Journal of the Japanese Society of Internal Medicine, 2009, 98, 1369-1371.	0.0	0
71	Dynamic Functional Relay between Insulin Receptor Substrate 1 and 2 in Hepatic Insulin Signaling during Fasting and Feeding. Cell Metabolism, 2008, 8, 49-64.	16.2	204
72	Total insulin and IGF-I resistance in pancreatic \hat{l}^2 cells causes overt diabetes. Nature Genetics, 2006, 38, 583-588.	21.4	239

#	Article	IF	Citations
73	Overexpression of Monocyte Chemoattractant Protein-1 in Adipose Tissues Causes Macrophage Recruitment and Insulin Resistance. Journal of Biological Chemistry, 2006, 281, 26602-26614.	3.4	746
74	Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatology Research, 2005, 33, 185-192.	3.4	87
75	Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10422-10427.	7.1	350
76	Suppressor of Cytokine Signaling 1 (SOCS- 1) and SOCS- 3 Cause Insulin Resistance through Inhibition of Tyrosine Phosphorylation of Insulin Receptor Substrate Proteins by Discrete Mechanisms. Molecular and Cellular Biology, 2004, 24, 5434-5446.	2.3	582
77	Increased insulin sensitivity in mice lacking p85Â subunit of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 419-424.	7.1	228
78	Molecular Balance between the Regulatory and Catalytic Subunits of Phosphoinositide 3-Kinase Regulates Cell Signaling and Survival. Molecular and Cellular Biology, 2002, 22, 965-977.	2.3	254
79	Restored insulin-sensitivity in IRS-1–deficient mice treated by adenovirus-mediated gene therapy. Journal of Clinical Investigation, 2000, 105, 1437-1445.	8.2	52
80	The Mechanism of Insulin-induced Signal Transduction Mediated by the Insulin Receptor Substrate Family. Endocrine Journal, 1999, 46, S25-S34.	1.6	41
81	Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes. Journal of Cellular Physiology, 1998, 175, 239-246.	4.1	44
82	Growth Hormone-Induced Tyrosine Phosphorylation of EGF Receptor as an Essential Element Leading to MAP Kinase Activation and Gene Expression. Endocrine Journal, 1998, 45, S27-S31.	1.6	54
83	Vascular endothelial growth factor (VEGF) activates Raf-1, mitogen-activated protein (MAP) kinases, and S6 kinase (p90rsk) in cultured rat cardiac myocytes., 1998, 175, 239.		1
84	Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone. Nature, 1997, 390, 91-96.	27.8	268
85	Angiotensin II Partly Mediates Mechanical Stress–Induced Cardiac Hypertrophy. Circulation Research, 1995, 77, 258-265.	4.5	244
86	Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature, 1994, 372, 182-186.	27.8	988